Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceJoints & skin

Serrapeptase

Serrapeptase (serratiopeptidase) has a small, low-quality evidence base for reducing swelling and trismus after dental surgery, and essentially nothing supporting the sweeping claims about dissolving arterial plaque, scar tissue or mucus. Japan, where it was a prescription drug for decades, withdrew it in 2011 after it failed to show efficacy.

What the science says

  • Reduces swelling and trismus after third-molar surgery Limited evidence

    A 2018 systematic review and meta-analysis found serratiopeptidase reduced facial swelling and improved mouth opening versus placebo after impacted third-molar removal, but performed worse than corticosteroids, and the included trials were small and at high risk of bias. A 2021 randomized controlled trial reported similar modest benefits on swelling and trismus with little effect on pain.

  • Dissolves arterial plaque, scar tissue or blood clots Limited evidence

    These claims come from in-vitro fibrinolysis experiments, not from human studies. No clinical trial has shown that oral serrapeptase alters atherosclerotic plaque, fibrosis or thrombus in humans, and there is little evidence that meaningful amounts of intact enzyme reach the circulation.

  • Thins mucus in chronic airway disease Limited evidence

    A single small Italian trial reported reduced sputum viscosity in chronic bronchitis; it has not been replicated. Meanwhile, serrapeptase itself has been implicated in eosinophilic pneumonitis case reports.

  • Anti-inflammatory effect comparable to NSAIDs Limited evidence

    Head-to-head data are sparse and mostly from older, unblinded dental studies. Japan's regulator concluded in 2011 that post-marketing trials failed to demonstrate efficacy, and the product was withdrawn — a strong negative signal for a drug used there for over 40 years.

Dosage & safety

Studied doseStudies used 10-60 mg/day (roughly 20,000-120,000 SPU) in 2-3 divided doses, taken on an empty stomach at least 30 minutes before food, for 3-7 days perioperatively. Only enteric-coated forms survive gastric acid; non-enteric capsules are almost certainly inactivated in the stomach.
SafetyReported effects include nausea, abdominal pain, loss of appetite, cough and skin reactions. Case reports document eosinophilic pneumonitis, pneumonitis and severe hypersensitivity reactions. Because of possible fibrinolytic and antiplatelet activity, avoid with warfarin, DOACs, aspirin, clopidogrel or NSAIDs, and stop at least 2 weeks before surgery. It is not a licensed medicine in most countries and is no longer marketed as a prescription drug in Japan; quality and enzyme activity of supplements vary widely. Avoid in pregnancy, breastfeeding and bleeding disorders.

Scientific references

Where to buy

Solaray, Nattokinase Serrapeptase, Enteric Coated, 30 VegCaps

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Joints & skin